hVIVO (LON:HVO) Trading Up 23% - Here's What Happened

hVIVO plc (LON:HVO - Get Free Report) shares shot up 23% during trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.15). 24,253,932 shares traded hands during mid-day trading, an increase of 569% from the average session volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).

Wall Street Analysts Forecast Growth

Separately, Shore Capital reaffirmed a "buy" rating on shares of hVIVO in a report on Friday, May 30th.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The company has a market cap of £75.60 million, a price-to-earnings ratio of 4.41 and a beta of 0.97. The firm's 50-day moving average price is GBX 15.92 and its 200 day moving average price is GBX 17.70.

hVIVO (LON:HVO - Get Free Report) last issued its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. On average, sell-side analysts anticipate that hVIVO plc will post 1.5492958 EPS for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.